一项关于贝伐单抗进展后情况的观察性研究中的隐性偏差 - Suppr

Suppr

超能文献

Hidden biases in an observational study of bevacizumab beyond progression.

作者信息

Kopetz Scott, Abbruzzese James L

出版信息

J Clin Oncol. 2009 Apr 1;27(10):1732-3; author reply 1733. doi: 10.1200/JCO.2009.21.2084. Epub 2009 Mar 2.

DOI:10.1200/JCO.2009.21.2084

PMID:19255299

Abstract

摘要

相似文献

Hidden biases in an observational study of bevacizumab beyond progression.一项关于贝伐单抗进展后情况的观察性研究中的隐性偏差

J Clin Oncol. 2009 Apr 1;27(10):1732-3; author reply 1733. doi: 10.1200/JCO.2009.21.2084. Epub 2009 Mar 2.

Bevacizumab vs EGFR antibodies in metastatic colorectal cancer.贝伐单抗与表皮生长因子受体抗体治疗转移性结直肠癌的对比

Clin Adv Hematol Oncol. 2015 Feb;13(2):90-2.

The use of bevacizumab and trastuzumab beyond tumor progression: a new avenue in cancer treatment?

Rev Recent Clin Trials. 2009 Sep;4(3):163-7. doi: 10.2174/157488709789957682.

[CORECT registry].[CORECT注册库]

Klin Onkol. 2012;25(6):480-5.

[Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].[用于结直肠癌的单克隆抗体疗法：西妥昔单抗、帕尼单抗和贝伐单抗]

Rev Med Liege. 2009 May-Jun;64(5-6):274-8.

[Use of antibodies for colorectal cancer chemotherapy].[抗体在结直肠癌化疗中的应用]

Nihon Rinsho. 2014 Jan;72(1):114-9.

Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure.西妥昔单抗和贝伐单抗用于一名患有结直肠癌和终末期肾衰竭患者的可行性。

Oncology. 2007;72(3-4):209-10. doi: 10.1159/000112828. Epub 2007 Dec 21.

Bevacizumab and cetuximab for colorectal cancer.贝伐单抗和西妥昔单抗用于治疗结直肠癌。

Drug Ther Bull. 2006 May;44(5):37-40.

Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.贝伐单抗联合氟嘧啶类方案用于转移性结直肠癌一线治疗的安全性

Clin Colorectal Cancer. 2006 Sep;6(3):189-91. doi: 10.1016/S1533-0028(11)70281-X.

[A clinical experience in treatment with bevacizumab for unresectable colorectal cancer].

Gan To Kagaku Ryoho. 2008 Nov;35(12):2274-6.

引用本文的文献

APOBEC3G expression is correlated with poor prognosis in colon carcinoma patients with hepatic metastasis.载脂蛋白B mRNA编辑酶催化多肽样蛋白3G（APOBEC3G）的表达与发生肝转移的结肠癌患者的不良预后相关。

Int J Clin Exp Med. 2014 Mar 15;7(3):665-72. eCollection 2014.

Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy.多中心二期研究：一线贝伐珠单抗联合双药化疗治疗失败的转移性结直肠癌患者，二线采用贝伐珠单抗联合双药化疗。

Invest New Drugs. 2013 Feb;31(1):183-91. doi: 10.1007/s10637-012-9853-3. Epub 2012 Jul 11.

Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice.转移性结直肠癌的系统治疗：美国肿瘤医学实践中化疗和生物治疗的应用模式。

J Oncol Pract. 2010 Nov;6(6):301-7. doi: 10.1200/JOP.2010.000072.

[Current medicinal treatment of metastasized colorectal carcinoma].

Chirurg. 2010 Jun;81(6):507-15. doi: 10.1007/s00104-010-1892-8.

Treatment in advanced colorectal cancer: what, when and how?晚期结直肠癌的治疗：治疗什么、何时治疗以及如何治疗？

Br J Cancer. 2009 Jun 2;100(11):1704-19. doi: 10.1038/sj.bjc.6605061. Epub 2009 May 12.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验